A domestic-inventory announcement from a single vendor, citing third-party test documentation for tirzepatide and flagging near-term restock timelines for other peptides, has drawn recurring community attention over three consecutive days, prompting renewed scrutiny of supply-chain transparency and verification standards among researchers.

“US Warehouse Inventory Update T30 T20 T15 TESA5 SELANL10 SEMAX10 IGF-1 CP10 SLUPP-332 These are on the way --------------------------------------------------------------------- New inventory arriving at China warehouse MOT10 NAD+500 BB10 BPC10”

anon-eb410282f0ff, 2026-05-20 · 1 reactions

“US Warehouse Inventory Update T30 T20 T15 TESA5 SELANL10 SEMAX10 IGF-1 CP10 SLUPP-332 These are on the way --------------------------------------------------------------------- New inventory arriving at China warehouse MOT10 NAD+500 BB10 BPC10”

anon-eb410282f0ff, 2026-05-20 · 1 reactions

“US Warehouse Inventory Update T30 $110 T30: https://janoshik.com/tests/150518-Unnamed_Sample_5USGV7AK3H1A”

anon-eb410282f0ff, 2026-05-13 · 1 reactions

“US Warehouse Inventory Update----on the way T30 T20 T15 TESA5 SELANL10 SEMAX10 IGF-1 CP10 SLUPP-332”

anon-eb410282f0ff, 2026-05-21 · 1 reactions